Theralink Technologies Inc (THER)

[southern belle]

check this out Prince

$OBMP OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate

cBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first brick in the wall toward some seriously valuable IP.

The company is trading right now at a market cap of just $7.9M, making it practically free for the likes of Eli Lilly and Co (NYSE:LLY), Nymox Pharmaceutical Corporation (NASDAQ:NYMX), or Pfizer Inc. (NYSE:PFE), all of which have been hot on the trail of IP geared toward the prostate cancer market. A price tag under $100M for a viable play into that $7 billion prostate cancer market is a fine starting idea to a conversation among any of these players.

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.

The company also has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana.
Target Acquired

As noted above, there are a number of recent deals in the biotech space that suggest bigger players are currently very much in the hunt for targets that leap them forward in a variety of R&D pathways. Hill-Rom Holdings, Inc. (NYSE:HRC) recently paid $330M for Mortara. We also just saw Celgene Corporation (NASDAQ:CELG) take Anokion off the playing field. In similar fashion, and right up our current alley, Pfizer just scooped up Medivation Inc (NASDAQ:MDVN) primarily for their IP related to the prostate cancer market.

https://wallstreetpr.com/oncbiomune-pharmaceuticals-inc-otcmktsobmp-presents-interesting-picture-as-a-bite-size-buyout-candidate-37725